CISD3是一个预后生物标志物和治疗瘤的治疗标
Jie Li1,2, Han Yang1, Yixin Qi1
1Department of Urology, The Affiliated Hospital of Qingdao University, Qingdao, 266001, China.
Scientific reports
|October 8, 2024
概括
该研究显示,CISD3蛋白水平在癌症中较低,其过度表达通过破坏线粒体功能和促进细胞损伤来抑制瘤生长. CISD3显示出作为癌症预后生物标志物和治疗点的潜力.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物化学 生化学
背景情况:
- CISD3与线粒体功能和瘤发生有关.
- 了解CISD3的作用对于癌症研究至关重要.
研究的目的:
- 系统地分析各种癌症中CISD3表达,预后价值和免疫活性.
- 研究CISD3在癌症进展中的机制性作用及其作为生物标志物和治疗点的潜力.
主要方法:
- 公共数据库的生物信息分析 (表达,预后,免疫透).
- 对CISD3拷贝数变化,甲基化和蛋白质相互作用的分析.
- 实验验证包括细胞培养和体内小鼠模型.
- 关于线粒体功能,ROS,GSH/GSSG比率和膜潜力的机制研究.
主要成果:
- 在瘤中,CISD3 呈现出较高的mRNA,但较低的蛋白质水平,通过 lysosomal 途径降解.
- CISD3表达与瘤透免疫细胞相关,具有双重预后作用,特别是在细胞癌 (RCC) 中.
- CISD3副本数变异与同类重组缺陷和新抗原有关.
- 过度表达CISD3抑制了扩散,迁移,入侵和瘤生长,与线粒体功能障碍,ROS增加和铁灭诱导有关.
结论:
- CISD3在癌症中起着复杂的作用,可能充当瘤抑制剂.
- CISD3在线粒体新陈代谢和还原氧平衡中的参与对于其抗癌作用至关重要.
- CISD3是一个有前途的预后生物标志物和癌症治疗的治疗标.
相关概念视频
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
lncRNA - Long Non-coding RNAs
8.5K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.5K


